Anti-CD86 Antibody (7U834) is a Rabbit antibody targeting CD86. Anti-CD86 Antibody (7U834) can be used in FCM, ICC/IF.

IgG

7U834

Human

1. 4% Paraformaldehyde-fixed Daudi (H) cell; Antibody incubation with (CD86) monoclonal Antibody, unconjugated (TMAB-04090) 1: 100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, BF488) at 37°C for 90 min, DAPI (blue) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.
2. The Daudi (H) cells were incubated in 5% BSA to block non-specific protein-protein interactions (30 min at r. T.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green): Rabbit Anti-CD86 antibody (TMAB-04090, 1: 100); Isotype Control (orange): Rabbit IgG. Blank control (black): PBS. Acquisition of 20,000 events was performed.
3. The MJ (H) cells were incubated in 5% BSA to block non-specific protein-protein interactions (30 min at r. T.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green): Rabbit Anti-CD86 antibody (TMAB-04090, 1: 100); Isotype Control (orange): Rabbit IgG. Blank control (black): PBS. Acquisition of 20,000 events was performed.
4. 4% Paraformaldehyde-fixed MJ (H) cell; Antibody incubation with (CD86) monoclonal Antibody, unconjugated (TMAB-04090) 1: 100, 90 min at 37°C; followed by BF488 conjugated Goat Anti-Rabbit IgG antibody (green, BF488) at 37°C for 90 min, DAPI (blue) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.

FCM=1:50-100; ICC/IF=1:50-200

Monoclonal

Recombinant Protein: human CD86 protein

Human

CD86

T-lymphocyte activation antigen CD86

Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.